[Effect of prodigiozan on immune reactivity in patients with steroid-dependent bronchial asthma].
An optimum scheme of prodigiosan therapy was developed for patients with steroid-dependent bronchial asthma taking account of the hormonal and immunological status. First the drug was administered at a dose of 0.1 ml of 0.005% solution, then in 3-4 days the dose was increased (in good tolerance) up to 0.2-0.4-0.8-1.0 ml. After the first administration of the drug at a dose exceeding 0.1 ml herpes virus could be activated in the body. Course therapy producing a stimulating effect on the immune system, inhibited the occurrence of autoimmune manifestations, prolonged bronchial asthma remission, permitted the reduction of retention of a maintenance dose of glucocorticoids.
Andriukin
A A
AA
Marinin
V F
VF
Nastiukova
E G
EG
Dudkina
L N
LN
Niaĭkina
N Iu
NIu
D000328:Adult; D000937:Antigen-Antibody Reactions / Q000187:drug effects*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D011354:Prodigiozan / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors
D005938:Glucocorticoids; D011135:Polysaccharides, Bacterial; D011354:Prodigiozan
Vliianie prodigiozana na immunnuiu reaktivnost' bol'nykh steroidzavisimoĭ bronkhial'noĭ astmoĭ.